Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope Mar 26, 2019
Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting Mar 20, 2019
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs Mar 19, 2019
Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights Mar 19, 2019
Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference Mar 15, 2019
Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial Feb 25, 2019
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy Feb 21, 2019
Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting Feb 12, 2019
Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program Feb 6, 2019
